Isabella Ciccone, MPH

Findings from the phase 2 ADDRESS-LC trial, assessing BioVie’s bezisterim in patients with long COVID–related fatigue and cognitive impairment, are anticipated to be reported in the first half of 2026.

Phase 1 data presented at AAN 2026 suggest that investigational siRNA therapy RAG-17 may reduce key disease biomarkers and show early signs of clinical stabilization following a single dose in patients with SOD1-ALS.

New long-term and post hoc data presented at the 2026 AAN Annual Meeting highlighted durable efficacy, safety, and patient-centered outcomes with nipocalimab in antibody-positive generalized myasthenia gravis.

A duo of Baptist Health experts discussed emerging evidence suggesting that hormonal factors, sex-based clinical differences, and social roles contribute to distinct experiences for women with Parkinson disease.

The deputy director at Association of Movement Disorder Advanced Practice Providers (AMDAPP) recapped key themes in movement disorders presented at the 2026 AMDAPP conference. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The assistant professor in the Department of Chemistry and Biochemistry at University of Nevada, Las Vegas reflected on receiving the first MDA Research Momentum Award at the 2026 MDA Conference. [WATCH TIME: 2 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 24, 2026.

A recent study suggested that probiotic regimens and biomarker-guided strategies may be a promising signal for reducing excessive daytime sleepiness in patients with PD and CKD.

At AAN 2026, an associate professor of neurology at University of Washington discussed how delays in antiamyloid treatment initiation for early Alzheimer disease may be driven by real-world factors. [WATCH TIME: 5 minutes]

New findings from a post hoc analysis of 2 phase 3 trials, presented at AAN 2026, reported that a majority of participants with advanced Parkinson disease had no troublesome dyskinesia at follow-up.

The president at Cala Health discussed the clinical role, evidence base, and potential of the Cala kIQ Plus wearable TAPS therapy for patients with essential tremor and Parkinson disease at AAN 2026.

New findings presented at AAN 2025 showed that treatment with satralizumab was associated with a reduction in annualized relapse rate compared with placebo over 48 weeks in patients with MOGAD.

Data from the phase 2 Vibrance-1 trial showed that alixorexton was associated with improvements in patient-reported outcomes in adults with narcolepsy type 1 over up to 12 to 13 weeks of follow-up.

A living systematic review presented at AAN 2026 showed that GLP-1 receptor agonists demonstrated biomarker and real-world signals of neuroprotection in Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

A recently presented analysis at AAN 2026 reported comparable safety and tolerability between atogepant and erenumab, with atogepant demonstrating a greater likelihood of early response at 1 month in adults with migraine.

Real-world data of the ELEVATE-PD study, presented at AAN 2026, suggest that switching to IPX203 from other levodopa-based therapies may improve motor function in patients with Parkinson disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 17, 2026.

Findings from the phase 3 OCEANIC-STROKE study showed that the addition of asundexian, a factor XIa inhibitor, with antiplatelet therapy lowered recurrent ischemic stroke compared with placebo.

An exploratory analysis of a phase 3 trial showed that solriamfetol improved daytime wakefulness without producing consistent or clinically meaningful changes in nocturnal sleep quality measures.

In honor of International Pompe Day, held April 15, 2026, NeurologyLive reviewed recent studies on the latest research and evolving standards of care for Pompe disease.

The approved neurofilament light chain test offers a minimally invasive approach to assessing neuroaxonal damage, with potential to complement MRI in routine multiple sclerosis care.

A recent study revealed that a substantial proportion of patients with NMOSD required escalation from first-line immunosuppressants to rituximab, with baseline severe disability emerging as a key associated factor.

A recent population-based data analysis of Korean adults reported those with anxiety and certain sleep disturbances experienced longer durations of morning grogginess, known as sleep inertia.

A recent study reported that relapse prevention was the most influential factor in treatment selection, with respondents favoring profiles similar to ravulizumab over other approved options for NMOSD.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 10, 2026.

The director of neuromuscular medicine at Marcus Neuroscience Institute shared findings from an analysis presented at MDA 2026 that compared real-world infection rates associated with generalized myasthenia gravis therapies. [WATCH TIME: 8 minutes]

In recognition of National Public Health Week, held April 6-12, NeurologyLive summarizes recent literature showing that environmental exposures are associated with increased risk of neurologic disorders.